Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
Can-Fite BioPharma Ltd. announced its 2025 financial results and significant clinical progress, including positive safety data in a Phase 2a pancreatic cancer trial and a remarkable 9-year cancer-free survival in a liver cancer patient treated with Namodenoson. The company is advancing Namodenoson through Phase 3 trials for hepatocellular carcinoma…